NASDAQ:PODD - Insulet Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$99.11 +0.28 (+0.28 %)
(As of 03/20/2019 01:42 PM ET)
Previous Close$98.83
Today's Range$98.15 - $99.54
52-Week Range$70.80 - $108.90
Volume231,429 shs
Average Volume749,275 shs
Market Capitalization$5.88 billion
P/E Ratio1,982.20
Dividend YieldN/A
Beta1.6
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device. It also customizes the Omnipod System technology platform for the delivery of drugs over a specified interval of time, at an administered volume. The company sells and markets its Omnipod System through a combination of direct sales representatives and independent distributors. Insulet Corporation was founded in 2000 and is headquartered in Billerica, Massachusetts.

Receive PODD News and Ratings via Email

Sign-up to receive the latest news and ratings for PODD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:PODD
CUSIP45784P10
Phone978-600-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$563.82 million
Cash Flow$0.3260 per share
Book Value$3.59 per share

Profitability

Net Income$3.29 million

Miscellaneous

Employees1,169
Market Cap$5.88 billion
Next Earnings Date5/2/2019 (Estimated)
OptionableOptionable

Insulet (NASDAQ:PODD) Frequently Asked Questions

What is Insulet's stock symbol?

Insulet trades on the NASDAQ under the ticker symbol "PODD."

How were Insulet's earnings last quarter?

Insulet Co. (NASDAQ:PODD) announced its quarterly earnings data on Monday, February, 25th. The medical instruments supplier reported $0.16 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.06 by $0.10. The medical instruments supplier had revenue of $164.90 million for the quarter, compared to analyst estimates of $162.45 million. Insulet had a return on equity of 1.73% and a net margin of 0.58%. Insulet's revenue for the quarter was up 26.4% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.12) EPS. View Insulet's Earnings History.

When is Insulet's next earnings date?

Insulet is scheduled to release their next quarterly earnings announcement on Thursday, May 2nd 2019. View Earnings Estimates for Insulet.

What guidance has Insulet issued on next quarter's earnings?

Insulet issued an update on its first quarter 2019 earnings guidance on Monday, February, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $152-156 million, compared to the consensus revenue estimate of $155.97 million.Insulet also updated its FY 2019 guidance to EPS.

What price target have analysts set for PODD?

11 equities research analysts have issued 12-month price targets for Insulet's shares. Their predictions range from $90.00 to $115.00. On average, they expect Insulet's share price to reach $101.6364 in the next twelve months. This suggests a possible upside of 2.9% from the stock's current price. View Analyst Price Targets for Insulet.

What is the consensus analysts' recommendation for Insulet?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 2 hold ratings, 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Insulet.

What are Wall Street analysts saying about Insulet stock?

Here are some recent quotes from research analysts about Insulet stock:
  • 1. According to Zacks Investment Research, "Insulet has been outperforming its industry over the past year. We are encouraged by the year-over-year improvement in net loss and revenues on solid uptake of Omnipod system in the United States in the last reported quarter. Expanding global customer base also drove revenues. Furthermore, expanding gross margin buoys optimism. We are also upbeat about Insulet’s solid progress with respect to its four-pillar strategy. Further, the receipt of FDA nod for the company’s Omnipod DASH Insulin Management System boosts investor confidence. Meanwhile, management expects the shifting to direct operations in Europe to continue to mar international revenues. Moreover, Insulet is exposed to risks associated with a weaker global economy and lower reimbursement rates." (10/4/2018)
  • 2. Canaccord Genuity analysts commented, "We maintain our BUY rating on PODD following the announcement that the company has secured two new OUS distributor partnerships with Theras Group (Italy) and Nordic Infucare (Nordic countries) effective July 1, 2018. Both distributors will provide sales, marketing, and customer support in their respective regions. We are encouraged to see PODD not only executing on OUS transition milestones but securing experienced medical device distributors in OUS countries. We believe the market exit by JNJ/Animas has created a unique opportunity for pump players – basically everyone ex Medtronic – to step into existing distribution/service networks who were left looking for new products when JNJ announced it was shuttering Animas. Thus, while not underestimating the resources required to build out an OUS commercial organization, the news of these two partnerships leaves us incrementally confident in Insulet’s ability to facilitate a smooth OUS transition." (5/2/2018)

Has Insulet been receiving favorable news coverage?

Headlines about PODD stock have trended somewhat positive this week, InfoTrie reports. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Insulet earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave news coverage about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days.

Who are some of Insulet's key competitors?

What other stocks do shareholders of Insulet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include Alibaba Group (BABA), DexCom (DXCM), Splunk (SPLK), Tandem Diabetes Care (TNDM), Veeva Systems (VEEV), Netflix (NFLX), Canopy Growth (CGC), NVIDIA (NVDA), Adobe (ADBE) and Arista Networks (ANET).

Who are Insulet's key executives?

Insulet's management team includes the folowing people:
  • Ms. Shacey Petrovic, Pres, CEO & Director (Age 45)
  • Mr. Michael L. Levitz, Sr. VP, CFO & Treasurer (Age 45)
  • Mr. Charles Alpuche, Exec. VP & COO (Age 59)
  • Mr. Patrick J. Sullivan, Consultant (Age 67)
  • Dr. Aiman Abdel-Malek, Exec. VP & Chief Technology Officer (Age 61)

Who are Insulet's major shareholders?

Insulet's stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (14.88%), Frontier Capital Management Co. LLC (2.95%), American Century Companies Inc. (1.33%), Norges Bank (1.14%), Eagle Asset Management Inc. (0.94%) and KAMES CAPITAL plc (0.80%). Company insiders that own Insulet stock include Aiman Abdel-Malek, Bradley A Thomas, Charles Alpuche, David A Lemoine, David Colleran, James C Mullen, Jessica Hopfield, John A Fallon, Michael L Levitz, Michael P Spears and Shacey Petrovic. View Institutional Ownership Trends for Insulet.

Which institutional investors are selling Insulet stock?

PODD stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Frontier Capital Management Co. LLC, Think Investments LP, Victory Capital Management Inc., Columbus Circle Investors, KAMES CAPITAL plc, Chartwell Investment Partners LLC and Triodos Investment Management BV. Company insiders that have sold Insulet company stock in the last year include Aiman Abdel-Malek, David A Lemoine, David Colleran, John A Fallon, Michael L Levitz, Michael P Spears and Shacey Petrovic. View Insider Buying and Selling for Insulet.

Which institutional investors are buying Insulet stock?

PODD stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, First Trust Advisors LP, Standard Life Aberdeen plc, American Century Companies Inc., Jennison Associates LLC, Amundi Pioneer Asset Management Inc., New York State Common Retirement Fund and California Public Employees Retirement System. Company insiders that have bought Insulet stock in the last two years include Bradley A Thomas, Charles Alpuche, James C Mullen, Jessica Hopfield and Michael P Spears. View Insider Buying and Selling for Insulet.

How do I buy shares of Insulet?

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Insulet's stock price today?

One share of PODD stock can currently be purchased for approximately $98.75.

How big of a company is Insulet?

Insulet has a market capitalization of $5.85 billion and generates $563.82 million in revenue each year. The medical instruments supplier earns $3.29 million in net income (profit) each year or $0.05 on an earnings per share basis. Insulet employs 1,169 workers across the globe.

What is Insulet's official website?

The official website for Insulet is http://www.insulet.com.

How can I contact Insulet?

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]


MarketBeat Community Rating for Insulet (NASDAQ PODD)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  529 (Vote Outperform)
Underperform Votes:  464 (Vote Underperform)
Total Votes:  993
MarketBeat's community ratings are surveys of what our community members think about Insulet and other stocks. Vote "Outperform" if you believe PODD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PODD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/20/2019 by MarketBeat.com Staff

Featured Article: Google Finance

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel